REFERENCES
- Umeda T, Ishii T, Hatakeyama K, Wakita H. Chemotherapy for soft tissue sarcoma—current concepts and review. Gan-To-Kagaku-Ryodo 1993; 20 (13): 1937–44.
- Elias AD. Chemotherapy for soft tissue sarcomas. Clin Orthoped 1993; 289: 94–103.
- Kampe CE, Rosen G, Eilber F et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with local-ized disease. Cancer 1993; 72 (7): 2169-9.
- Steward \VP, Verweij J, Somers R et al. The use of recombinant human granulocyte-macrophage colony-stimulat-ing factor with combination chemotherapy in the treatment of advanced adult soft tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993; 31 (2): 241-4.
- Stuart-Harris R, Dailey D, Bell DR, Levi J, Simes RJ, Wiltshaw E. Ifosfamide combination regimens for soft-tissue sarcoma. Cancer Chemother Parmacol 1993; 31 (2): 185–8.
- Ogawa M. The role of granulocyte colony-stimulating factor with dose-intensive chemotherapy. Sem Oncol 1994; 21 (1): 7–9.
- Green M. Dose-intensive chemotherapy with cytokine support. Sem Oncol 1994; 21 (1): 1–6.
- American Joint Committee Staging Manual, Philadelphia: J.B. Lippincott 1987.
- WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication, Geneva, Switzerland, World Health Organization, 1979.
- BMDP/Dynamic User's Guide Release. 7.0. Vol:1, BMDP Statistical Software Inc.1983.
- O'Bryan RM, Baker LH, Gottlieb JE et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39: 1940–1948.
- Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the MD Anderson experience. Cancer Chemother Pharmacol 1993; 3 (2): 174–179.
- Bronchud MH, Howell A, Crowther D et al.The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121–125.
- Schutte J, Mouridsen HT, Steward W et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990; 26: 558–561.
- Antman K, Crowley J, Balcerzak S et al. An intergroup phase III randomised study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. J Clin Oncol 1993; 11 (7): 1276–1285.
- Diaz-Rubio E, Adrover E. Use of granulocyte growth factors in solid tumours. Eur J Cancer 1994; 30 (1): 120–122.
- Van-Globbeke M, Van-Oostelom AT, Steward W, Verweij J, Mouridsen H. Selection of large and objectively measurable target lesions in EORTC pase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Eur J Cancer 1993; 29 A (14): 1943-7.